FDA Updates Raltegravir (Isentress) Labeling
“On April 8, 2014 FDA approved updates to the Isentress (raltegravir) label to include information regarding co-adminsitration of raltegravir with boceprevir or telaprevir.
“In drug interaction studies, raltegravir did not have a clinically meaningful effect on the pharmacokinetics of telaprevir or boceprevir. No dose adjustment is required for Isentress or boceprevir or telaprevir.”
The revised label is available at the FDA website.
More information is available:
FDA: Press release
AIDSinfo: Raltegravir (Isentress) patient fact sheet
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - Category: Infectious Diseases Source Type: news
More News: Department of Health | Health | HIV AIDS | Incivek | Infectious Diseases | Isentress | Study | Websites